Insights

Gathering insights about Passage…

Similar companies to Passage

Passage Tech Stack

Passage uses 8 technology products and services including Varnish, cdnjs, Google Workspace, and more. Explore Passage's tech stack below.

Varnish
Caching
cdnjs
Content Delivery Network
Google Workspace
Email
Clipboard.js
Javascript Libraries
jQuery
Javascript Libraries
Cloudflare Bot Management
Security
HSTS
Security
HTTP/3
Web & Portal Technology

Media & News

Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Price Target at $42.67
Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) has been given an average rating of "Moderate Buy" by the four research firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and three have issued a buy rating on the company. The average twelve-month
Jan 14, 2026 | www.defenseworld.net
Analyzing Passage Bio (NASDAQ:PASG) and Vir Biotechnology (NASDAQ:VIR)
Passage Bio (NASDAQ: PASG - Get Free Report) and Vir Biotechnology (NASDAQ: VIR - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, institutional ownership and valuation. Insider and Institutional Ownership 53.5% of Passage
Dec 27, 2025 | www.defenseworld.net
Financial Comparison: Passage Bio (NASDAQ:PASG) versus PepGen (NASDAQ:PEPG)
Passage Bio (NASDAQ: PASG - Get Free Report) and PepGen (NASDAQ: PEPG - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations. Insider and Institutional Ownership 53.5% of Passage Bio
Dec 07, 2025 | www.defenseworld.net
Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Target Price at $42.67
Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) has been assigned an average rating of "Moderate Buy" from the four ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and three have given a buy rating to the company. The average twelve-month target price
Nov 25, 2025 | www.defenseworld.net
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights
Actively enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) patients in ongoing upliFT-D study Aligned with the U.S. Food and Drug Administration (FDA) on an analytical approach to establish comparability of a high-productivity, suspension-based PBFT02 manufacturing process On track to obtain regulatory feedback on FTD-GRN registrational trial design in 1H 2026 Cash runway into 1Q 2027 PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the third quarter ended September 30, 2025, and provided recent business highlights. “We are pleased to report that we have opened enrollment in our third FTD-GRN and first FTD-C9orf72 patient cohorts in our ongoing upliFT-D clinical trial of PBFT02.
Nov 10, 2025 | www.globenewswire.com
Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference
PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will participate in a fireside chat during the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on Wednesday, November 12, 2025 at 9:30 a.m. ET in Boston, MA.
Nov 05, 2025 | www.globenewswire.com
Passage Bio to Participate in Chardan's 9th Annual Genetic Medicines Conference
PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will participate in a panel discussion during the Chardan 9th Annual Genetic Medicines Conference on Tuesday, October 21, 2025 at 3:30 p.m. ET in New York City.
Oct 14, 2025 | www.globenewswire.com

Passage's Email Address Formats

Passage uses at least 1 format(s):

Passage Email Formats	Example	Percentage
First@passage.studio	John@passage.studio	45%
Last@passage.studio	Doe@passage.studio	5%
First.Last@passage.studio	John.Doe@passage.studio	5%
First@passage.studio	John@passage.studio	45%

Frequently Asked Questions

Where is Passage's headquarters located?

Passage's main headquarters is located at 28 South Park St, San Francisco, California 94107, US. The company has employees across 4 continents, including North AmericaAfricaAsia.

What is Passage's stock symbol?

Passage is a publicly traded company; the company's stock symbol is PASG.

What is Passage's official website and social media links?

Passage's official website is passage.studio and has social profiles on LinkedIn.

What is Passage's NAICS code?

Passage's NAICS code is 5414 - Specialized Design Services.

How many employees does Passage have currently?

As of December 2025, Passage has approximately 16 employees across 4 continents, including North AmericaAfricaAsia. Key team members include Head Of Product And Tech: S. R.Vp, Design & Principal: Z. S.Director Of Growth & Partnerships: N. W.. Explore Passage's employee directory with LeadIQ.

What industry does Passage belong to?

Passage operates in the Design Services industry.

What technology does Passage use?

Passage's tech stack includes VarnishcdnjsGoogle WorkspaceClipboard.jsjQueryCloudflare Bot ManagementHSTSHTTP/3.

What is Passage's email format?

Passage's email format typically follows the pattern of First@passage.studio. Find more Passage email formats with LeadIQ.

When was Passage founded?

Passage was founded in 2020.

Passage

Q: What is Passage's official website and social media links?

Passage's official website is passage.studio. Passage has social profiles on LinkedIn.

Q: How many employees does Passage have currently?

Passage has approximately 16 employees.

Q: What technology does Passage use?

Passage's tech stack includes GoDaddy, Open Graph, Cloudflare Bot Management, Google Fonts API, Varnish.

Design ServicesUnited States11-50 Employees

Passage brings software applications and platforms to life for a host of businesses—from startups to enterprise companies. Specializing in clean technology and the medical space, with deep experience across many categories, we’re ready roll up our sleeves and get to work for you.